![Sample our Engineering & Technology journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5933/TOC-Subject-Sample-2021-Engineering-Tech.jpg"})
Abstract
This month‘s snapshot of events in the therapeutic delivery arena covers the period 21 June–21 July 2010 inclusive. Overall it was a highly successful month for companies working in the field, with five products based on nonstandard formulation technologies achieving regulatory approval either in the USA or in the EU. It also saw a number of business negotiations come to fruition, including the announced merger between Biovail and Valeant and the takeover of Abraxis by Celgene. However, the period also witnessed some disappointments, one of the most notable of which is Pfizer‘s planned withdrawal of Mylotarg® from the market. The information is sourced from company websites and press releases.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.